{"transactions":[{"id":4613529,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-09T21:00:46.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":8500,"derivative":{"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001178913-26-004471","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1625184/000117891326004471/ownership.xml","form_type":"4"}},{"id":4613528,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-09-09T21:00:46.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033 and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":17000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001178913-26-004471","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1625184/000117891326004471/ownership.xml","form_type":"4"}},{"id":4103,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & COO"}}],"security":"Restricted Stock Units","published_at":"2026-09-04T10:00:25.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":56000,"derivative":{"underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001742727-26-000002","document":"form4-09042026_060917.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1742727/000174272726000002/form4-09042026_060917.xml","form_type":"4"}},{"id":4102,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T10:00:25.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":112000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034, and (v) options to purchase 50,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":112000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":112000},"source":{"system":"sec-edgar","filing":"0001742727-26-000002","document":"form4-09042026_060917.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742727/000174272726000002/form4-09042026_060917.xml","form_type":"4"}},{"id":4111,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2681,"kind":"person","name":"Elze Christian","position":1,"cik":"0002075661","reported_name":"Elze Christian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-04T10:00:23.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":8500,"derivative":{"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0002075661-26-000002","document":"form4-09042026_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2075661/000207566126000002/form4-09042026_060913.xml","form_type":"4"}},{"id":4110,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2681,"kind":"person","name":"Elze Christian","position":1,"cik":"0002075661","reported_name":"Elze Christian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-09-04T10:00:23.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":17000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0002075661-26-000002","document":"form4-09042026_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2075661/000207566126000002/form4-09042026_060913.xml","form_type":"4"}},{"id":4093,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-04T10:00:23.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":8500,"derivative":{"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001614890-26-000002","document":"form4-09042026_060915.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614890/000161489026000002/form4-09042026_060915.xml","form_type":"4"}},{"id":4092,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-09-04T10:00:23.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033 and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":17000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001614890-26-000002","document":"form4-09042026_060915.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614890/000161489026000002/form4-09042026_060915.xml","form_type":"4"}},{"id":4095,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-04T10:00:21.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":8500,"derivative":{"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001454771-26-000002","document":"form4-09042026_060910.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1454771/000145477126000002/form4-09042026_060910.xml","form_type":"4"}},{"id":4094,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-09-04T10:00:21.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":17000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001454771-26-000002","document":"form4-09042026_060910.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454771/000145477126000002/form4-09042026_060910.xml","form_type":"4"}},{"id":4099,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2675,"kind":"person","name":"Bar-Shalev Amos","position":1,"cik":"0001385113","reported_name":"Bar-Shalev Amos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-04T10:00:19.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":8500,"derivative":{"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001385113-26-000002","document":"form4-09042026_060907.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385113/000138511326000002/form4-09042026_060907.xml","form_type":"4"}},{"id":4098,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2675,"kind":"person","name":"Bar-Shalev Amos","position":1,"cik":"0001385113","reported_name":"Bar-Shalev Amos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-09-04T10:00:19.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":17000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001385113-26-000002","document":"form4-09042026_060907.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385113/000138511326000002/form4-09042026_060907.xml","form_type":"4"}},{"id":4097,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2026-09-04T10:00:19.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":160000,"derivative":{"underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001781450-26-000002","document":"form4-09042026_060904.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781450/000178145026000002/form4-09042026_060904.xml","form_type":"4"}},{"id":4096,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T10:00:19.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":320000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029, (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":320000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":320000},"source":{"system":"sec-edgar","filing":"0001781450-26-000002","document":"form4-09042026_060904.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781450/000178145026000002/form4-09042026_060904.xml","form_type":"4"}},{"id":4105,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-04T10:00:17.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":8500,"derivative":{"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001935668-26-000002","document":"form4-09042026_060909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1935668/000193566826000002/form4-09042026_060909.xml","form_type":"4"}},{"id":4104,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-09-04T10:00:17.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032, (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":17000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001935668-26-000002","document":"form4-09042026_060909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1935668/000193566826000002/form4-09042026_060909.xml","form_type":"4"}},{"id":4101,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2676,"kind":"person","name":"Forster Eliot","position":1,"cik":"0001831558","reported_name":"Forster Eliot","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-04T10:00:14.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":8500,"derivative":{"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001831558-26-000003","document":"form4-09042026_060901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831558/000183155826000003/form4-09042026_060901.xml","form_type":"4"}},{"id":4100,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2676,"kind":"person","name":"Forster Eliot","position":1,"cik":"0001831558","reported_name":"Forster Eliot","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-09-04T10:00:14.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 85,715 shares of common stock at an exercise price equal to $1.75 per share that expire on September 14, 2033, and (ii) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":17000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001831558-26-000003","document":"form4-09042026_060901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831558/000183155826000003/form4-09042026_060901.xml","form_type":"4"}},{"id":960132,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2025-12-23T12:25:58.000Z","date":"2025-12-19","kind":"purchase","planned":false,"acquired":true,"shares":56000,"price":1.81,"value":101360.0,"ownership":{"direct":true},"balance_after":188516,"source":{"system":"sec-edgar","filing":"0001781450-25-000005","document":"form4-12232025_121255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000178145025000005/form4-12232025_121255.xml","form_type":"4"}},{"id":994436,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2675,"kind":"person","name":"Bar-Shalev Amos","position":1,"cik":"0001385113","reported_name":"Bar-Shalev Amos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-19T21:34:55.000Z","date":"2025-11-18","kind":"sale","planned":false,"acquired":false,"shares":168,"price":1.87,"value":314.16,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001385113-25-000005","document":"form4-11192025_091151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000138511325000005/form4-11192025_091151.xml","form_type":"4"}},{"id":1048618,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2676,"kind":"person","name":"Forster Eliot","position":1,"cik":"0001831558","reported_name":"Forster Eliot","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-09-04T21:00:24.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Does not include options to purchase 85,715 shares of common stock at an exercise price equal to $1.75 per share that expire on September 14, 2033,"}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-023708","document":"form4-09042025_050917.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023708/form4-09042025_050917.xml","form_type":"4"}},{"id":1048617,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2676,"kind":"person","name":"Forster Eliot","position":1,"cik":"0001831558","reported_name":"Forster Eliot","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-04T21:00:24.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001415889-25-023708","document":"form4-09042025_050917.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023708/form4-09042025_050917.xml","form_type":"4"}},{"id":1048616,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-09-04T21:00:24.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-023706","document":"form4-09042025_050913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023706/form4-09042025_050913.xml","form_type":"4"}},{"id":1048615,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-04T21:00:24.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing\nupon the date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001415889-25-023706","document":"form4-09042025_050913.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023706/form4-09042025_050913.xml","form_type":"4"}},{"id":1048614,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-09-04T21:00:22.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-023705","document":"form4-09042025_050911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023705/form4-09042025_050911.xml","form_type":"4"}},{"id":1048613,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-04T21:00:22.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing\nupon the date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001415889-25-023705","document":"form4-09042025_050911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023705/form4-09042025_050911.xml","form_type":"4"}},{"id":1048612,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2681,"kind":"person","name":"Elze Christian","position":1,"cik":"0002075661","reported_name":"Elze Christian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-09-04T21:00:21.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-023707","document":"form4-09042025_050915.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023707/form4-09042025_050915.xml","form_type":"4"}},{"id":1048611,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2681,"kind":"person","name":"Elze Christian","position":1,"cik":"0002075661","reported_name":"Elze Christian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-04T21:00:21.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing\nupon the date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001415889-25-023707","document":"form4-09042025_050915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023707/form4-09042025_050915.xml","form_type":"4"}},{"id":1048610,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-09-04T21:00:21.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-023704","document":"form4-09042025_050909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023704/form4-09042025_050909.xml","form_type":"4"}},{"id":1048609,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-04T21:00:21.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001415889-25-023704","document":"form4-09042025_050909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023704/form4-09042025_050909.xml","form_type":"4"}},{"id":1048608,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-09-04T21:00:18.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032, (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 23, 2033."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-023703","document":"form4-09042025_050907.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023703/form4-09042025_050907.xml","form_type":"4"}},{"id":1048607,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-04T21:00:18.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001415889-25-023703","document":"form4-09042025_050907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023703/form4-09042025_050907.xml","form_type":"4"}},{"id":1048606,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2675,"kind":"person","name":"Bar-Shalev Amos","position":1,"cik":"0001385113","reported_name":"Bar-Shalev Amos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-09-04T21:00:14.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-023702","document":"form4-09042025_050905.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023702/form4-09042025_050905.xml","form_type":"4"}},{"id":1048605,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2675,"kind":"person","name":"Bar-Shalev Amos","position":1,"cik":"0001385113","reported_name":"Bar-Shalev Amos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-04T21:00:14.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001415889-25-023702","document":"form4-09042025_050905.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023702/form4-09042025_050905.xml","form_type":"4"}},{"id":1048604,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-04T21:00:11.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034."}],"balance_after":50000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-023701","document":"form4-09042025_050903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023701/form4-09042025_050903.xml","form_type":"4"}},{"id":1048603,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Common Stock","published_at":"2025-09-04T21:00:11.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":225817,"source":{"system":"sec-edgar","filing":"0001415889-25-023701","document":"form4-09042025_050903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023701/form4-09042025_050903.xml","form_type":"4"}},{"id":1048602,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-04T21:00:10.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":340000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029 and (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032."}],"balance_after":340000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":340000},"source":{"system":"sec-edgar","filing":"0001415889-25-023700","document":"form4-09042025_050901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023700/form4-09042025_050901.xml","form_type":"4"}},{"id":1048601,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2025-09-04T21:00:10.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":195000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":2344418,"source":{"system":"sec-edgar","filing":"0001415889-25-023700","document":"form4-09042025_050901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023700/form4-09042025_050901.xml","form_type":"4"}},{"id":1069331,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-12T20:30:07.000Z","date":"2025-06-10","kind":"purchase","planned":false,"acquired":true,"shares":129000,"price":1.596,"value":205884.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.60 to $1.575 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":303000,"source":{"system":"sec-edgar","filing":"0001415889-25-021494","document":"form4-08122025_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925021494/form4-08122025_040801.xml","form_type":"4"}},{"id":1376134,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Common Stock","published_at":"2024-11-05T22:00:15.000Z","date":"2024-09-23","kind":"grant","planned":false,"acquired":true,"shares":90909,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The original Form 4, filed on September 24, 2024, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the amount of restricted shares granted."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":660909,"source":{"system":"sec-edgar","filing":"0001415889-24-026168","document":"form4a-11052024_051110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588924026168/form4a-11052024_051110.xml","form_type":"4/A","original_submission_date":"2024-09-24"}},{"id":1400489,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Common Stock","published_at":"2024-09-24T21:00:09.000Z","date":"2024-09-23","kind":"grant","planned":false,"acquired":true,"shares":99010,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":669010,"source":{"system":"sec-edgar","filing":"0001415889-24-023907","document":"form4-09242024_050905.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588924023907/form4-09242024_050905.xml","form_type":"4"}},{"id":1400488,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-24T21:00:07.000Z","date":"2024-09-23","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025, (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (iii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 and (iv) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032."}],"balance_after":100000,"derivative":{"exercise_price":1.1,"expiration_date":"2034-09-23","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-24-023906","document":"form4-09242024_050902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588924023906/form4-09242024_050902.xml","form_type":"4"}},{"id":1551109,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-04-03T21:30:27.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":263960,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":2149418,"source":{"system":"sec-edgar","filing":"0001415889-24-010099","document":"form4-04032024_050412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588924010099/form4-04032024_050412.xml","form_type":"4"}},{"id":1757071,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2023-10-20T10:50:07.000Z","date":"2023-10-19","kind":"purchase","planned":false,"acquired":true,"shares":16129,"price":1.41,"value":22741.89,"ownership":{"direct":true},"balance_after":132516,"source":{"system":"sec-edgar","filing":"0001415889-23-014454","document":"form4-10202023_061001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588923014454/form4-10202023_061001.xml","form_type":"4"}},{"id":1757070,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2023-10-20T10:50:07.000Z","date":"2023-10-19","kind":"purchase","planned":false,"acquired":true,"shares":48387,"price":1.4,"value":67741.8,"ownership":{"direct":true},"balance_after":116387,"source":{"system":"sec-edgar","filing":"0001415889-23-014454","document":"form4-10202023_061001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588923014454/form4-10202023_061001.xml","form_type":"4"}},{"id":1768755,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-10-03T21:00:58.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":61676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032."}],"balance_after":61676,"derivative":{"exercise_price":1.66,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":61676},"source":{"system":"sec-edgar","filing":"0001415889-23-013903","document":"form4-10032023_051035.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588923013903/form4-10032023_051035.xml","form_type":"4"}},{"id":1768754,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-10-03T21:00:54.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":61676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032."}],"balance_after":61676,"derivative":{"exercise_price":1.66,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":61676},"source":{"system":"sec-edgar","filing":"0001415889-23-013902","document":"form4-10032023_051032.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588923013902/form4-10032023_051032.xml","form_type":"4"}},{"id":1768753,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2675,"kind":"person","name":"Bar-Shalev Amos","position":1,"cik":"0001385113","reported_name":"Bar-Shalev Amos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-10-03T21:00:51.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":61676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032."}],"balance_after":61676,"derivative":{"exercise_price":1.66,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":61676},"source":{"system":"sec-edgar","filing":"0001415889-23-013901","document":"form4-10032023_051025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588923013901/form4-10032023_051025.xml","form_type":"4"}},{"id":1768752,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-03T21:00:50.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":61676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032 and (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032."}],"balance_after":61676,"derivative":{"exercise_price":1.66,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":61676},"source":{"system":"sec-edgar","filing":"0001415889-23-013899","document":"form4-10032023_051016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588923013899/form4-10032023_051016.xml","form_type":"4"}},{"id":1768751,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-03T21:00:32.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":61676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032."}],"balance_after":61676,"derivative":{"exercise_price":1.66,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":61676},"source":{"system":"sec-edgar","filing":"0001415889-23-013900","document":"form4-10032023_051021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588923013900/form4-10032023_051021.xml","form_type":"4"}},{"id":1780469,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2676,"kind":"person","name":"Forster Eliot","position":1,"cik":"0001831558","reported_name":"Forster Eliot","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-09-15T20:46:57.000Z","date":"2023-09-14","kind":"grant","planned":false,"acquired":true,"shares":85715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."}],"balance_after":85715,"derivative":{"exercise_price":1.75,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":85715},"source":{"system":"sec-edgar","filing":"0001104659-23-101237","document":"tm2326155d2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465923101237/tm2326155d2_4.xml","form_type":"4"}},{"id":1804395,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-17T20:30:58.000Z","date":"2023-08-15","kind":"grant","planned":false,"acquired":true,"shares":800000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. Of such shares, 200,000 shares were fully-vested upon grant and the remaining 600,000 shares vest over a two-year period beginning on the date of grant in eight equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":1885458,"source":{"system":"sec-edgar","filing":"0001104659-23-093073","document":"tm2324046-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465923093073/tm2324046-4_4seq1.xml","form_type":"4"}},{"id":1804393,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Common Stock","published_at":"2023-08-17T20:30:42.000Z","date":"2023-08-15","kind":"grant","planned":false,"acquired":true,"shares":201903,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":570000,"source":{"system":"sec-edgar","filing":"0001104659-23-093070","document":"tm2324046-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465923093070/tm2324046-3_4seq1.xml","form_type":"4"}},{"id":1804392,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":110479,"kind":"person","name":"Hayon Yael","position":1,"cik":"0001817121","reported_name":"Hayon Yael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Research & Development"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-08-17T20:30:28.000Z","date":"2023-08-15","kind":"grant","planned":false,"acquired":true,"shares":35115,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030 and options to purchase 250,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 9, 2032."}],"balance_after":35115,"derivative":{"exercise_price":1.99,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":35115},"source":{"system":"sec-edgar","filing":"0001104659-23-093069","document":"tm2324046-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465923093069/tm2324046-2_4seq1.xml","form_type":"4"}},{"id":1804391,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":110479,"kind":"person","name":"Hayon Yael","position":1,"cik":"0001817121","reported_name":"Hayon Yael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Research & Development"}}],"security":"Common Stock","published_at":"2023-08-17T20:30:28.000Z","date":"2023-08-15","kind":"grant","planned":false,"acquired":true,"shares":35115,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended (the \"Plan\"). The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":35115,"source":{"system":"sec-edgar","filing":"0001104659-23-093069","document":"tm2324046-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465923093069/tm2324046-2_4seq1.xml","form_type":"4"}},{"id":1804390,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Common Stock","published_at":"2023-08-17T20:30:12.000Z","date":"2023-08-15","kind":"grant","planned":false,"acquired":true,"shares":187344,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":200817,"source":{"system":"sec-edgar","filing":"0001104659-23-093066","document":"tm2324046-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465923093066/tm2324046-1_4seq1.xml","form_type":"4"}},{"id":2063872,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T22:08:38.000Z","date":"2023-01-03","kind":"purchase","acquired":true,"shares":110000,"price":1.4165,"value":155815.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.430 to $1.405 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":174000,"source":{"system":"sec-edgar","filing":"0001104659-23-001495","document":"tm232297-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465923001495/tm232297-1_4seq1.xml","form_type":"4"}},{"id":2162621,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:04:40.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032."}],"balance_after":10000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-22-098956","document":"tm2225460-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098956/tm2225460-10_4seq1.xml","form_type":"4"}},{"id":2162620,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:04:21.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":340000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025, (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028 and (iii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030."}],"balance_after":340000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":340000},"source":{"system":"sec-edgar","filing":"0001104659-22-098953","document":"tm2225460-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098953/tm2225460-9_4seq1.xml","form_type":"4"}},{"id":2162619,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":110479,"kind":"person","name":"Hayon Yael","position":1,"cik":"0001817121","reported_name":"Hayon Yael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Research & Development"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:03:38.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030."}],"balance_after":250000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001104659-22-098951","document":"tm2225460-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098951/tm2225460-8_4seq1.xml","form_type":"4"}},{"id":2162707,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:03:02.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 80,000 shares of common stock at an exercise price equal to $2.00 per share that expire on September 22, 2029."}],"balance_after":350000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001104659-22-098950","document":"tm2225460-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098950/tm2225460-7_4seq1.xml","form_type":"4"}},{"id":2162618,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:02:43.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029."}],"balance_after":750000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001104659-22-098949","document":"tm2225460-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098949/tm2225460-6_4seq1.xml","form_type":"4"}},{"id":2162617,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:02:10.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030."}],"balance_after":50000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-22-098948","document":"tm2225460-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098948/tm2225460-5_4seq1.xml","form_type":"4"}},{"id":2162616,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":123917,"kind":"person","name":"Bronfeld Zeev","position":1,"cik":"0001298522","reported_name":"Bronfeld Zeev","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:01:49.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended, or if the Reporting Person ends his tenure on the Board of Directors within 12 months of the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 240,000 shares of common stock at an exercise price equal to $3.70 per share that expire on February 3, 2030."}],"balance_after":100000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-22-098947","document":"tm2225460-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098947/tm2225460-4_4seq1.xml","form_type":"4"}},{"id":2162615,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2675,"kind":"person","name":"Bar-Shalev Amos","position":1,"cik":"0001385113","reported_name":"Bar-Shalev Amos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:01:29.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030."}],"balance_after":50000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-22-098945","document":"tm2225460-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098945/tm2225460-3_4seq1.xml","form_type":"4"}},{"id":2162614,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:01:09.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030."}],"balance_after":50000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-22-098944","document":"tm2225460-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098944/tm2225460-2_4seq1.xml","form_type":"4"}},{"id":2162613,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:00:44.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030."}],"balance_after":50000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-22-098941","document":"tm2225460-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098941/tm2225460-1_4seq1.xml","form_type":"4"}},{"id":2215582,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2678,"kind":"person","name":"Ben Zvi Shmuel","position":1,"cik":"0001935668","reported_name":"Ben Zvi Shmuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-07-05T20:32:55.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."}],"balance_after":40000,"derivative":{"exercise_price":1.09,"expiration_date":"2032-06-30","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-22-077380","document":"tm2220369-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922077380/tm2220369-1_4seq1.xml","form_type":"4"}},{"id":2297952,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-04-13T20:05:46.000Z","date":"2022-04-11","kind":"purchase","acquired":true,"shares":68000,"price":1.5,"value":102000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person holds the shares in an account with his spouse as joint tenants."}],"balance_after":68000,"source":{"system":"sec-edgar","filing":"0001104659-22-045488","document":"tm2212654-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922045488/tm2212654-1_4seq1.xml","form_type":"4"}},{"id":2369934,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Common Stock","published_at":"2022-02-28T22:02:20.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":121951,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":368097,"source":{"system":"sec-edgar","filing":"0001104659-22-028159","document":"tm227910-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922028159/tm227910-2_4seq1.xml","form_type":"4"}},{"id":2369933,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-28T22:01:13.000Z","date":"2022-02-25","kind":"grant","acquired":true,"shares":637531,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":1085458,"source":{"system":"sec-edgar","filing":"0001104659-22-028157","document":"tm227910-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922028157/tm227910-1_4seq1.xml","form_type":"4"}},{"id":2684420,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":1,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":2,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T21:40:30.000Z","date":"2021-06-03","kind":"sale","acquired":false,"shares":857506,"price":2.2534,"value":1932304.0204,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.200 to $2.450, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Dexcel Pharma Technologies Ltd (\"DPT\") and Dan Oren, DPT's Executive Chairman, are filing this Form 4 because they have beneficial ownership over common stock of Protalix BioTherapeutics, Inc. The shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT."}],"balance_after":3637314,"source":{"system":"sec-edgar","filing":"0001104659-21-076488","document":"tm2118431-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465921076488/tm2118431-1_4seq1.xml","form_type":"4"}},{"id":2684419,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":122424,"kind":"organization","name":"Dexcel Pharma Technologies Ltd.","position":1,"cik":"0001720007","reported_name":"Dexcel Pharma Technologies Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122426,"kind":"person","name":"Oren Dan","position":2,"cik":"0001636701","reported_name":"Oren Dan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T21:40:30.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":61211,"price":2.5576,"value":156553.2536,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dexcel Pharma Technologies Ltd (\"DPT\") and Dan Oren, DPT's Executive Chairman, are filing this Form 4 because they have beneficial ownership over common stock of Protalix BioTherapeutics, Inc. The shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.530 to $2.565, inclusive."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Dexcel Pharma Technologies Ltd (\"DPT\") and Dan Oren, DPT's Executive Chairman, are filing this Form 4 because they have beneficial ownership over common stock of Protalix BioTherapeutics, Inc. The shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT."}],"balance_after":4494820,"source":{"system":"sec-edgar","filing":"0001104659-21-076488","document":"tm2118431-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465921076488/tm2118431-1_4seq1.xml","form_type":"4"}},{"id":3057693,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Common Stock","published_at":"2020-08-14T21:01:49.000Z","date":"2020-08-11","kind":"grant","acquired":true,"shares":246146,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The original Form 4, filed on August 13, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the vesting schedule of the restricted shares."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the \"Plan\"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the \"Plan\"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":246146,"source":{"system":"sec-edgar","filing":"0001104659-20-095626","document":"tm2027654-2_4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920095626/tm2027654-2_4a.xml","form_type":"4/A","original_submission_date":"2020-08-13"}},{"id":3057694,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-08-14T21:01:00.000Z","date":"2020-08-11","kind":"grant","acquired":true,"shares":447927,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The original Form 4, filed on August 13, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the vesting schedule of the restricted shares."},{"field":"security","element":"securityTitle","label":"F2","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the \"Plan\"). The restricted shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the \"Plan\"). The restricted shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":447927,"source":{"system":"sec-edgar","filing":"0001104659-20-095623","document":"tm2027654-1_4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920095623/tm2027654-1_4a.xml","form_type":"4/A","original_submission_date":"2020-08-13"}},{"id":3059114,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP and CFO"}}],"security":"Common Stock","published_at":"2020-08-13T21:03:11.000Z","date":"2020-08-11","kind":"grant","acquired":true,"shares":246146,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the \"Plan\"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":246146,"source":{"system":"sec-edgar","filing":"0001104659-20-094755","document":"tm2027548d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920094755/tm2027548d3_4.xml","form_type":"4"}},{"id":3059115,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-08-13T21:02:48.000Z","date":"2020-08-11","kind":"grant","acquired":true,"shares":447927,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the \"Plan\").  Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest.  Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":447927,"source":{"system":"sec-edgar","filing":"0001104659-20-094753","document":"tm2027548d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920094753/tm2027548d2_4.xml","form_type":"4"}},{"id":3059111,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-08-13T21:01:36.000Z","date":"2020-08-11","kind":"grant","acquired":true,"shares":122656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025 and (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028."}],"balance_after":122656,"derivative":{"exercise_price":3.59,"expiration_date":"2030-08-11","underlying":"Common Stock","underlying_shares":122656},"source":{"system":"sec-edgar","filing":"0001104659-20-094751","document":"tm2027548d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920094751/tm2027548d1_4.xml","form_type":"4"}},{"id":3086969,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":110479,"kind":"person","name":"Hayon Yael","position":1,"cik":"0001817121","reported_name":"Hayon Yael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Research & Development"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-07-08T21:01:21.000Z","date":"2020-07-05","kind":"grant","acquired":true,"shares":129771,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."}],"balance_after":129771,"derivative":{"exercise_price":3.73,"expiration_date":"2030-07-05","underlying":"Common Stock","underlying_shares":129771},"source":{"system":"sec-edgar","filing":"0001104659-20-082116","document":"tm2024387d2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920082116/tm2024387d2_4.xml","form_type":"4"}},{"id":3119205,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":148640,"kind":"person","name":"Almon Einat Brill","position":1,"cik":"0001385116","reported_name":"Almon Einat Brill","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Development Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-06-08T21:07:44.000Z","date":"2020-06-07","kind":"grant","acquired":true,"shares":196995,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 25,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025; and (ii) options to purchase 70,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2025."}],"balance_after":196995,"derivative":{"exercise_price":3.59,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":196995},"source":{"system":"sec-edgar","filing":"0001104659-20-070906","document":"tm2022027d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920070906/tm2022027d1_4.xml","form_type":"4"}},{"id":3178191,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T20:05:23.000Z","date":"2020-04-07","kind":"purchase","acquired":true,"shares":64000,"price":2.426,"value":155264.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $2.39 to $2.53. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":64000,"source":{"system":"sec-edgar","filing":"0001104659-20-045926","document":"tm2015785d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920045926/tm2015785d1_4.xml","form_type":"4"}},{"id":3289501,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":123917,"kind":"person","name":"Bronfeld Zeev","position":1,"cik":"0001298522","reported_name":"Bronfeld Zeev","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2020-02-05T22:01:05.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."}],"balance_after":240000,"derivative":{"exercise_price":3.7,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001104659-20-011315","document":"tm205452-3_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920011315/tm205452-3_4.xml","form_type":"4"}},{"id":3305490,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":41298,"kind":"person","name":"Granot David","position":1,"cik":"0001551620","reported_name":"Granot David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2020-01-22T22:03:26.000Z","date":"2020-01-20","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."}],"balance_after":40000,"derivative":{"exercise_price":3.55,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-20-005972","document":"tm205452-6_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920005972/tm205452-6_4.xml","form_type":"4"}},{"id":3305489,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2675,"kind":"person","name":"Bar-Shalev Amos","position":1,"cik":"0001385113","reported_name":"Bar-Shalev Amos","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2020-01-22T22:03:06.000Z","date":"2020-01-20","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."}],"balance_after":40000,"derivative":{"exercise_price":3.55,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-20-005971","document":"tm205452-5_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920005971/tm205452-5_4.xml","form_type":"4"}},{"id":3305488,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2020-01-22T22:02:42.000Z","date":"2020-01-20","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."}],"balance_after":40000,"derivative":{"exercise_price":3.55,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-20-005970","document":"tm205452-4_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920005970/tm205452-4_4.xml","form_type":"4"}},{"id":3305487,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2673,"kind":"person","name":"Boudes Pol F","position":1,"cik":"0001454771","reported_name":"Boudes Pol F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2020-01-22T22:02:13.000Z","date":"2020-01-20","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."}],"balance_after":40000,"derivative":{"exercise_price":3.55,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-20-005967","document":"tm205452-2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920005967/tm205452-2_4.xml","form_type":"4"}},{"id":3305486,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2672,"kind":"person","name":"Melincoff Gwen A","position":1,"cik":"0001614890","reported_name":"Melincoff Gwen A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2020-01-22T22:01:51.000Z","date":"2020-01-20","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."}],"balance_after":40000,"derivative":{"exercise_price":3.55,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-20-005965","document":"tm205452-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920005965/tm205452-1_4.xml","form_type":"4"}},{"id":3407273,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55603,"kind":"person","name":"Rubin Eyal","position":1,"cik":"0001721411","reported_name":"Rubin Eyal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & CFO"}}],"security":"Stock Options (Right to Buy)","published_at":"2019-09-24T21:01:16.000Z","date":"2019-09-22","kind":"grant","acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."}],"balance_after":800000,"derivative":{"exercise_price":0.2,"expiration_date":"2029-09-22","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001144204-19-045806","document":"tv530009_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420419045806/tv530009_4.xml","form_type":"4"}},{"id":3472379,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2674,"kind":"person","name":"Bashan Dror","position":1,"cik":"0001781450","reported_name":"Bashan Dror","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2019-07-02T21:56:38.000Z","date":"2019-06-30","kind":"grant","acquired":true,"shares":1600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."}],"balance_after":1600000,"derivative":{"exercise_price":0.469,"expiration_date":"2029-06-30","underlying":"Common Stock","underlying_shares":1600000},"source":{"system":"sec-edgar","filing":"0001144204-19-033654","document":"tv524753_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420419033654/tv524753_4.xml","form_type":"4"}},{"id":3816210,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":120543,"kind":"person","name":"Maimon Yossi","position":1,"cik":"0001385115","reported_name":"Maimon Yossi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-14T20:31:39.000Z","date":"2018-09-13","kind":"grant","acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (ii) options to purchase 250,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025."}],"balance_after":700000,"derivative":{"exercise_price":0.56,"expiration_date":"2028-09-13","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001144204-18-049524","document":"tv502884_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420418049524/tv502884_4.xml","form_type":"4"}},{"id":3816209,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":148640,"kind":"person","name":"Almon Einat Brill","position":1,"cik":"0001385116","reported_name":"Almon Einat Brill","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Product Development"}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-14T20:31:21.000Z","date":"2018-09-13","kind":"grant","acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (ii) options to purchase 250,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025."}],"balance_after":700000,"derivative":{"exercise_price":0.56,"expiration_date":"2028-09-13","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001144204-18-049522","document":"tv502883_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420418049522/tv502883_4.xml","form_type":"4"}},{"id":3816208,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-14T20:30:59.000Z","date":"2018-09-13","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; (ii) options to purchase 115,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (iii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025."}],"balance_after":600000,"derivative":{"exercise_price":0.56,"expiration_date":"2028-09-13","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001144204-18-049521","document":"tv502882_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420418049521/tv502882_4.xml","form_type":"4"}},{"id":3816207,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":163616,"kind":"person","name":"Manor Moshe","position":1,"cik":"0001623532","reported_name":"Manor Moshe","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-14T20:30:40.000Z","date":"2018-09-13","kind":"grant","acquired":true,"shares":1300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 900,000 shares of common stock at an exercise price equal to $2.37 per share that expire on September 29, 2024."}],"balance_after":1300000,"derivative":{"exercise_price":0.56,"expiration_date":"2028-09-13","underlying":"Common Stock","underlying_shares":1300000},"source":{"system":"sec-edgar","filing":"0001144204-18-049517","document":"tv502881_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420418049517/tv502881_4.xml","form_type":"4"}},{"id":3816206,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":163615,"kind":"person","name":"Shaaltiel Yoseph","position":1,"cik":"0001385118","reported_name":"Shaaltiel Yoseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, R&D"}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-14T20:30:18.000Z","date":"2018-09-13","kind":"grant","acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; (ii) options to purchase 145,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (iii) options to purchase 275,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025."}],"balance_after":700000,"derivative":{"exercise_price":0.56,"expiration_date":"2028-09-13","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001144204-18-049515","document":"tv502880_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420418049515/tv502880_4.xml","form_type":"4"}},{"id":4319104,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":163616,"kind":"person","name":"Manor Moshe","position":1,"cik":"0001623532","reported_name":"Manor Moshe","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2017-05-16T13:31:21.000Z","date":"2017-05-16","kind":"purchase","acquired":true,"shares":50000,"price":0.81,"value":40500.0,"ownership":{"direct":true},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001144204-17-027803","document":"v467168_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420417027803/v467168_4.xml","form_type":"4"}},{"id":4531992,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":88462,"kind":"organization","name":"Camber Capital Management LP","position":1,"cik":"0001444043","reported_name":"Camber Capital Management LLC","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2016-12-06T20:26:01.000Z","date":"2016-12-02","kind":"sale","acquired":false,"shares":2500000,"price":0.3168,"value":792000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities reported herein for Camber Capital Management LLC (the \"LLC\" ) represent Common Stock beneficially owned and held of record by Camber Capital Master Fund, L.P. (the \"Master Fund\"), another private investment fund (the \"Fund\") and one managed account (the \"Managed Account\") for which the LLC serves as the investment manager. Stephen DuBois is the managing member of the LLC and managing member of the general partner for the Fund and the Master Fund. The LLC, the Master Fund, the Fund, the Managed Account, general partner and Mr. DuBois (the \"Reporting Persons\") are each beneficial owners and have an address of 101 Huntington Avenue, Floor 21, Boston, MA 02199. The Reporting Persons disclaim beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares in which the Reporting Persons have no actual pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Of the securities reported for this transaction, 2,413,466 shares of Common Stock were sold for the account of the Master Fund, 16,998 shares of Common Stock were sold for the account of the Fund, and 69,536 shares of Common Stock were sold for the account of the Managed Account."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"As of the closing of trading on December 06, 2016, 10,402,037 shares of Common Stock were held for the account of the Master Fund, 73,262 shares of Common Stock were held for the account of the Fund, and 299,701 shares of Common Stock were held for the account of the Managed Account."}],"balance_after":10775000,"source":{"system":"sec-edgar","filing":"0001354488-16-008627","document":"issuerdirect_section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000135448816008627/issuerdirect_section16.xml","form_type":"4"}},{"id":4601888,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":163615,"kind":"person","name":"Shaaltiel Yoseph","position":1,"cik":"0001385118","reported_name":"Shaaltiel Yoseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, R&D"}}],"security":"Stock Options (Right to Buy)","published_at":"2016-09-16T21:01:28.000Z","date":"2016-09-15","kind":"exercise","acquired":false,"shares":122162,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents exercise of all stock underlying the derivative security."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents exercise of all stock underlying the derivative security."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include options to purchase 263,728 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018; options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; options to purchase 145,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and options to purchase 275,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025."}],"balance_after":0,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":122162},"source":{"system":"sec-edgar","filing":"0001144204-16-124284","document":"v448888_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420416124284/v448888_4.xml","form_type":"4"}},{"id":4601887,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":163615,"kind":"person","name":"Shaaltiel Yoseph","position":1,"cik":"0001385118","reported_name":"Shaaltiel Yoseph","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP, R&D"}}],"security":"Common Stock","published_at":"2016-09-16T21:01:28.000Z","date":"2016-09-15","kind":"exercise","acquired":true,"shares":122162,"price":0.001,"value":122.162,"ownership":{"direct":true},"balance_after":585916,"source":{"system":"sec-edgar","filing":"0001144204-16-124284","document":"v448888_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420416124284/v448888_4.xml","form_type":"4"}}]}